Linezolid for the treatment of multidrug-resistant tuberculosis
Linezolid for the treatment of multidrug-resistant tuberculosis
复制标题
DOI：
10.1093/jac/dki148
复制
发表时间：
2005-07-01
影响因子：
5.2
通讯作者：
Moreno, S
中科院分区：
文献类型：
--
作者：
Fortún, J;Martín-Dávila, P;Moreno, S
目的：体外研究显示利奈唑胺对结核分枝杆菌（包括多重耐药菌株）具有良好的活性。然而，临床经验利奈唑胺在tuberculo.Methods：我们报告了我们的临床经验与5例多重耐药结核病感染的联合治疗方案，其中包括利奈唑胺。结果：两名患者有多重耐药牛分枝杆菌感染，耐12种抗结核药物（其中一人与艾滋病毒合并感染和< 50 CD 4细胞/mm（3））。另外3例为多重耐药M.结核菌株，对所有一线药物和其他二线药物都有耐药性。所有患者均接受利奈唑胺联合噻醋松、氯法齐明或阿莫西林/克拉维汀治疗。药敏试验显示利奈唑胺MIC值
Objectives: In vitro studies have shown good activity of linezolid against Mycobacterium tuberculosis, including multidrug-resistant strains. However, clinical experience with linezolid in tuberculosis is scarce.Methods: We report our clinical experience with five consecutive patients with multidrug-resistant tuberculosis infection treated with combination regimens that included linezolid.Results: Two patients had multidrug-resistant Mycobacterium bovis infection, with resistance to 12 antituberculous agents (one of them with HIV co-infection and < 50 CD4 cells/mm(3)). The other three patients were infected by multidrug-resistant M. tuberculosis strains, with resistance to all first-line drugs and other second-line drugs. All patients received linezolid in combination with thiacetazone, clofazimine or amoxicillin/clavulanate. Susceptibility tests showed linezolid MIC values